Engage Bio

Potent, durable, and redosable non-viral genetic medicines

HealthcareTherapeuticsSynthetic BiologyBiotechDrug discovery http://engagebio.com ↗

Company facts

Early-stage
Founded
2022
Employees
10
Headquarters
United States

About

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.